- Tytuł:
- A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial
- Autorzy:
- Źródło:
- International Journal of Diabetes in Developing Countries: Incorporating Diabetes Bulletin. 44(1):67-76
Czasopismo naukowe